Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535

Phase 3positiveHRS-7535/KAI-7535Positive

AI Analysis

Summary

Kailera Therapeutics and Hengrui Pharma announced positive topline data from two Phase 3 clinical trials of HRS-7535/KAI-7535, an oral small molecule GLP-1 receptor agonist. The positive results from both trials represent a significant advancement for the oral GLP-1 program.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Positive topline data from two Phase 3 clinical trials

Importance:7/10

Sentiment:

0.75

GLP-1 receptor agonistoral small moleculePhase 3positive datadiabetes

Related Companies

$KLRA $JHPCY

Read the original article

Published by yahoo_finance on July 7, 2026 11:00 AM

Read Original